That model is now breaking down, because the nature of the user has fundamentally changed. An AI agent isn't a person and doesn't occupy a seat. It can do the work of ten analysts simultaneously without triggering a single additional license under the old logic. IDC projects that by 2028, the pure seat-based model will be obsolete and 70% of vendors will be forced to rethink their value proposition as AI agents displace manual labor. Forbes ran a headline in March 2026: "AI Is Killing The Seat License. Venture Capital Isn’t Ready For What’s Next."

We've watched a sweeping correction across software companies against this backdrop, regardless of their financial health or their capacity to integrate into the new technological axis. So in this piece I want to try to answer a few questions.

• Which segment of the software industry is most insulated from this devaluation?

• Why does the noise around Claude Mythos represent an opportunity and not a risk?

• And finally, how do you get there first?

In “Equilibrium” I laid out the Caballero model and the three stable states of the IT ecosystem, arguing that we’re currently inside Region II, the AI deployment zone where returns on capital hold at a plateau. In “SaaS Armageddon” I broke down how that same AI is undermining the seat-based model of enterprise software, shifting value from human hours to machine time. But in both pieces I deliberately left one sector untouched. One that behaves in a fundamentally different way from the rest of software.

Cybersecurity.

The Sector That Feeds on Chaos

Read more

Coherent is a global technology leader in materials, lasers, and components for telecommunications. Founded in 1971, the company has spent more than 50 years evolving into a vertically integrated supplier of advanced solutions for telecommunications, from materials and components to subsystems and systems. It serves several end markets.

Products and Markets

Industrial: fiber lasers used for battery laser welding, particularly in EV battery manufacturing, and in the production of advanced medical devices. Ultraviolet lasers used in semiconductor and display equipment, covering everything from ingots to packaged integrated circuits, as well as in the production of OLED displays for mobile devices and micro-LEDs for high-end televisions and large displays. The portfolio also includes complex laser systems and subsystems for a wide range of industrial applications including aerospace and defense, laser components, optics and crystals, and high-performance materials such as ceramics, metal matrix composites, and diamond materials.

Telecommunications: embedded coherent transceivers, which are devices used in optical telecom networks to transmit large volumes of data over long distances via fiber optic cables using laser technology. The key differentiator of coherent transceivers is sophisticated signal processing on both the transmit and receive sides, enabling data transmission at far higher speeds and over much greater distances with less loss and distortion compared to conventional optical transceivers. This makes coherent transceivers critical for building the high-speed backbone and metro networks of modern telecom operators and cloud providers. These transceivers support data rates from 100 to 800 Gbps, while conventional optical transceivers top out at 400 Gbps. Coherent is ahead of the competition on speed. The telecom portfolio also includes datacom transceivers for expanding cloud infrastructure bandwidth (with AI/ML components), wavelength selective switches for optical network routing, embedded optical line subsystems for network flexibility and scalability, pump lasers for terrestrial and submarine telecom systems, and laser diodes based on indium phosphide (InP) and gallium arsenide (GaAs) vertical-cavity surface-emitting lasers (VCSELs). InP lasers are widely used as light sources for optical transceivers in telecom equipment; GaAs VCSELs are widely used in optical interfaces for short-reach links inside and between servers in data centers, as well as in consumer electronics, sensors, and other devices. Both types are valued for their small size, energy efficiency, and integrability into optical data transmission circuits.

Electronics: Coherent produces and supplies high-technology components for consumer and automotive electronics. Its sensors are used in AR/VR devices and wearables for health monitoring. Lasers support 3D sensing and precision distance measurement. In vehicles, the company’s components improve EV performance and autonomous driving systems. The company also develops materials and optics for improved displays and communications systems.

Instrumentation: Coherent produces components and systems for instrumentation in medicine and science, including technologies for smart healthcare, rapid and precise medical diagnostics, and personalized medicine. For scientific research, the company develops environmental monitoring instruments and advanced research tools. Coherent also offers optics, lasers, and thermoelectric components used in biotechnology and environmental research, consistently bringing new innovations to market.

Revenue Structure

The company’s ten-year average revenue CAGR is 25%. Five significant acquisitions also contributed to this revenue growth. From all of the above, the natural question is: where does the money actually come from? The deliberate emphasis on telecommunications earlier was intentional.

The two markets generating the most revenue are industrial and telecommunications. Industrial revenue is driven by demand for laser systems for EV welding. Laser use in semiconductor and electronics manufacturing also falls under industrial: precision material processing in the semiconductor sector requires lasers to achieve the tolerances needed.

Telecom revenue growth is driven by demand for 800G and higher transceivers for data centers serving AI applications and cloud computing. AI development is pushing humanity to a new technological level, and new technologies require more speed. According to Coherent management’s forecast, the dominant data transmission standard over the next five years will be 800G/1.6T.

Companies are progressively migrating to fiber optic links to increase bandwidth. 5G network expansion also requires large quantities of optical components and high-speed transceivers. Based on current projections, 5G adoption will continue growing for the next five years, which will support revenue growth.

Coherent Corp. operates across multiple continents, and there is a geopolitical risk from China. A trade war could partially reduce the company’s earnings, which is worth factoring in when buying the stock. But the broad diversification of production and supply chains may allow the company to weather such challenges.

Valuation

Tracking the Return on Equity and Price-to-Book multiple together is one of the core principles of financial analysis and stock valuation.

Return on Equity measures the profitability of equity capital, specifically how efficiently a company uses its capital to generate earnings.

Price-to-Book compares the market value of a company to its book value, meaning the amount shareholders would theoretically receive in a liquidation after all assets are sold and all debts paid.

Low ROE and low P/B points to problems: a company that uses its capital inefficiently, trading below book value. High ROE and high P/B indicates a successful company with efficient capital use, reflected in a high market valuation.

What conclusions can we draw from the metric trends at Coherent?

ROE is negative as of Q2’24, but it is higher than in the prior quarters (Q4’23 and Q1’24). Negative ROE means the company is running losses and carries a high debt load. Both are true, but they are driven primarily by investment in the business.

Price-to-Book stands at 1.73, below the IT sector average of 3.18 and below the industry average of 2.92. Relative to both benchmarks, the company is priced at roughly half. P/B has also been rising for three consecutive quarters.

Net income: over the last four quarters, the company has been rapidly climbing out of losses on the back of revenue growth and operating income tied to...

Net debt: debt has been declining steadily for seven consecutive quarters. In the most recent quarter, the company paid down $58M of debt and refinanced its $2.4B credit facility, cutting the interest rate by 0.25%, saving $9M per year. As a result of these improvements in earnings and debt, Moody’s upgraded the company’s credit rating to Ba2, reinforcing expectations of further financial improvement.

Based on the matrix framework described above, further improvement in the Price-to-Book and Return on Equity metrics should be expected.

Most Recent Shareholder Call

Coherent Corp. reported strong results for Q3 of fiscal year 2024 (the company’s fiscal year differs from the calendar year), supported by strong positions across several key market segments. While 800G transceiver demand for data centers and AI applications was the primary growth driver, the company is demonstrating technological leadership across a broader range of areas.

In the 800G/1.6T transceiver segment, Coherent continues to grow revenue and expand its customer base. The company also announced progress in developing 200mm silicon carbide wafers to meet growing demand. Executive VP Sohail Khan noted that the company “is shipping engineering samples to several customers, and the feedback from them is very good.”

In the materials segment, a new optical circuit switch (OCS) based on liquid crystal technology was announced, potentially opening new growth opportunities. Chief Technology Officer Julie Sheridan Eng noted that Coherent is already in sample supply discussions with many customers.

In lasers and photonics, CTO Julie Sheridan Eng highlighted the company’s advantages in developing VCSEL, EML, and silicon photonics technologies for the next generation of 1.6T/3.2T transceivers.

In telecom, despite a slower-than-expected overall market recovery, Coherent sees growth opportunity in China and in the digital coherent optics module market through its differentiated products.

On the financial side, Coherent raised its full-year revenue and earnings guidance to $4.62-4.70B and non-GAAP EPS to $1.56-1.73, supported by business diversification. Temporary margin headwinds have been resolved or are in the process of being addressed.

Operating cash flow remains strong at $117M for the quarter. Temporary gross profit headwinds from manufacturing issues have been resolved.

As CEO Chuck Mattera summarized: “We have 300 years of experience in our management team. We will show investors the depth of our technology, our markets, and the business as a whole. The best is yet to come.” He is probably right.

Shareholders

Insider ownership stands at just 1.57%, with the controlling interest in the hands of outside investors. Institutional interest is high: 88.63% of all shares are held by institutions. The largest positions belong to Vanguard Group Inc. (10.08%), Dodge & Cox Inc. (9.90%), and BlackRock Inc. (8.07%). Also worth noting is Stanley Druckenmiller’s fund, Duquesne Family Office LLC, which holds 1.66% of the company, representing 3.5% of his portfolio.

Conclusion

Coherent is a multi-layered company with broad product diversification. The first thing I see in Coherent’s outlook is growth in the customer base for 800G transceiver sales, driven by AI/ML scaling. The second is growth in telecom equipment sales for 5G, as that technology continues to expand.

There is also a large volume of products tied to automotive, computers, and portable devices. But those will likely lag due to elevated inflation and interest rates. Consumers may simply cut back on new gadgets and electronics, which would weigh on sales of those components. However, these factors may ultimately have limited impact on overall revenues given the company’s diversified business lines.

Declining debt, gradually improving earnings, positive guidance from management, high analyst ratings, and a company priced well below fair value: compelling arguments for a medium-term buy.

Core areas of NVIDIA’s business:

• GPU production: the GeForce series for gaming and graphics work, the Quadro and Tesla series for workstations and data centers.

• Tegra system-on-chip (SoC) production for mobile devices.

• Software development: the DirectX and Vulkan graphics APIs, the CUDA and cuDNN frameworks for neural network acceleration, image processing technologies.

• AI, machine learning, and computer vision platforms: the NVIDIA DGX deep learning platform, NVIDIA AI model libraries and frameworks, the NVIDIA Drive platform for autonomous vehicles, NVIDIA Omniverse for 3D design and virtual worlds.

• GeForce NOW hardware for game streaming and cloud services built on its own technology stack.

The company develops both hardware and software across all of these areas.

NVIDIA’s primary competitors in GPUs and AI solutions: AMD in discrete GPUs (Radeon cards, data center and supercomputing GPUs); Intel with its integrated and discrete GPU lineup and AI solutions including Habana Labs; Qualcomm and Apple with mobile SoCs that include GPUs and neural engines; Samsung with Exynos SoCs and AI development efforts; Amazon with its cloud AI chips Trainium and Inferentia. On the startup side: Tenstorrent (AI chips for automotive and robotics), Graphcore (Colossus processors for ML), and Cerebras Systems (CS-1 and CS-2 deep learning chips). Not all of these competitors are publicly traded.

Artificial intelligence is not another fad like the metaverse or NFTs. Once you integrate AI tools into your workflow, the productivity gains are obvious. More and more people are discovering these technologies and incorporating them into daily life, paying for subscriptions to AI-powered apps and services. Now consider the optimization potential for large enterprises: cost reduction, margin expansion, throughput improvement. Every company wants this.

The fact that NVIDIA leads in AI-specific chip production explains the sales trajectory. Calling NVIDIA a bubble is wrong. The company validates its valuation every quarter with earnings that no other company in the world is currently matching.

Annual Financial Review

Income Statement

Revenue came in at $60.922B, up 126% year-over-year: an enormous jump driven by explosive demand for NVIDIA’s solutions, especially in the data center segment. Gross profit reached $44.301B, also sharply higher versus the prior period, pointing to improved business profitability. Operating income was $32.972B: NVIDIA continued investing in growth, pushing operating expenses higher, but the revenue surge kept operating profits at a high level. Net income hit a record $29.760B on the back of revenue and profit growth. EBITDA reached $34.480B, reflecting the high operational efficiency of NVIDIA’s business model.

These core financial metrics delivered impressive growth in 2023 and drove the stock performance. The numbers reflect NVIDIA’s leadership in accelerated computing and AI for data centers.

Balance Sheet

Total assets grew to a record $65.73B as of January 2024, up from $41.18B a year earlier, reflecting major investment in business expansion. Cash and short-term investments increased substantially to $25.98B from $13.3B, strengthening the company’s liquidity position. Total liabilities rose to $22.75B from $19.08B, though liabilities as a share of total funding fell to 34.6% from 46.2%, a strongly positive development. Equity nearly doubled to $42.98B from $22.1B, driven primarily by accumulated retained earnings. Total debt declined to $11.06B from $12.03B. Net debt turned negative at a record -$14.93B, a very positive indicator of the company’s liquidity position.

The company’s financial position strengthened materially across all of these metrics over the past year.

Cash Flows

Operating cash flow was a very strong $28.090B, indicating high profitability in the core business. Investing outflow of $10.566B reflects investment in securities and capital expenditures for business expansion. Financing outflow of $13.633B was driven primarily by $12.316B in share buybacks, which exceeded proceeds from new share issuance. Free cash flow came in at $27.02B, an excellent indicator of profitability and cash generation.

As of January 2024, the cash flow profile reflects a mature, high-yield business that is actively reinvesting in growth while simultaneously returning substantial capital to shareholders through buybacks.

Quarterly Financial Review

Income Statement

Revenue reached a record $22.1B, up 22% quarter-on-quarter and 265% year-on-year. The primary driver was the data center segment, where revenue rose 409% year-on-year to $18.4B on strong demand for Hopper architecture products for training and inference of generative AI models and LLMs. GAAP gross margin expanded to 76%, non-GAAP to 76.7%, reflecting the right component cost structure and the high weighting of the data center segment in revenue. GAAP operating expenses rose 6% quarter-on-quarter, non-GAAP 9%, due to investment in compute capacity, infrastructure, and headcount, though high gross profit absorbed these increases without impacting results. Net income hit a record $12.29B for the quarter, up 33% from the prior quarter ($9.243B). Quarterly EBITDA also reached a record, up 30% from the prior quarter ($10.789B), the result of unprecedented revenue growth at high margins.

Q4 FY2024 was an exceptional quarter: new records for net income and EBITDA, driven by explosive demand and high profitability.

Balance Sheet

Total assets grew to a record $65.73B from $41.18B a year earlier. Cash and short-term investments rose to $25.98B from $13.30B. Total liabilities increased to $22.75B from $19.08B, while their share of total funding declined to 34.6% from 46.4%. Equity grew to $42.98B from $22.10B, driven by retained earnings growth. Total debt edged down to $11.06B from $12.03B. Net debt turned negative at a record -$14.93B. The company's financial position strengthened substantially across all key metrics over the past year.

Cash Flows

Operating cash flow of $11.499B is a very strong result: the core business is generating a large cash inflow. Investing outflow of $6.109B reflects ongoing capital investment in infrastructure and growth. Financing outflow of $3.629B is driven primarily by $3.5B in share buybacks, exceeding proceeds from new share issuance. Free cash flow was a positive $11.25B, indicating the company can self-fund its growth from operating cash flows without external financing.

Shareholder Call

Negative

Following US export restrictions introduced in October 2023, NVIDIA did not receive licenses to supply certain products to China and was forced to suspend those shipments. Alternative products not requiring a license have been introduced, but the China business has contracted materially. Demand for NVIDIA products, particularly newer generations, significantly outpaces supply. The company is making large upfront payments to suppliers to secure manufacturing capacity, indicating dependence on their ability to deliver components. Management addressed these issues indirectly, but they could have a modest impact on future results.

Positive

Record quarterly revenue of $22.1B, up 22% sequentially and 265% year-on-year. Full-year revenue reached $60.9B, up 126%. Data center revenue for fiscal year 2024 was $47.5B, more than tripling year-on-year. Hopper architecture demand for AI acceleration and high-performance computing remains very strong, and the networking business exceeded a $13B annualized revenue run rate. The company made significant progress in software and services, with annualized Q4 revenue from that segment reaching $1B. Positive momentum across automotive, healthcare, financial services, and the “sovereign AI” concept for individual countries and regions building their own AI infrastructure. CEO Jensen Huang expressed confidence in continued growth conditions through calendar years 2024 and 2025 and beyond.

Risks

1. Supply chain and manufacturing capacity: supply shortages against high demand; dependence on component suppliers and their ability to ramp production; potential disruption from geopolitical factors.

2. Geopolitics: ongoing US export controls on China; operational difficulties in that market; broader instability affecting global supply chains. Taiwan Semiconductors plays an outsized role here, manufacturing the vast majority of NVIDIA’s chips. Any escalation of tensions around Taiwan creates a direct risk to production and supply.

3. Competition: intensifying competition in AI accelerators from other technology companies; risk of alternative or disruptive technologies emerging.

4. Technology: challenges in transitioning to new product generations and manufacturing processes; risk of delays in developing new architectures.

5. Operations: difficulty scaling rapidly into new markets, particularly software and sovereign AI; talent acquisition and retention risks.

6. Finance: market volatility affecting the stock price; currency risk from global operations.

All of these risks simply need to stay in view, with close attention to what management says about them. At present, the most material risks are supply chain and geopolitics.

Shareholders

The top holders are major financial institutions: Vanguard Group, BlackRock, and FMR, LLC. Their conviction is evident from the scale of their positions. Insiders hold 4% of shares, while institutional investors hold 68.03%. Over 70% of the total float is held by institutions, meaning roughly 30% of freely tradable shares are available to other market participants.

Conclusion

90% of the AI data center chip market. 80% of the total chip market. Revenue up 265% in the most recent quarter. Record quarterly net income of $12.29B, eight times higher than a year ago. New solutions in development including a superchip for quantum computing and chips for robotics. Growing sales across gaming, automotive, healthcare, and other AI-driven sectors. All one company.

Whatever happens with interest rates, what matters is corporate earnings. If NVIDIA continues to beat estimates, analyst forecasts will be revised upward again. Investors look at current data first, then build forward projections from it. The stock price ultimately follows future results.

If those future results disappoint, the stock will fall sharply. But NVIDIA’s chip architecture is far ahead of the competition. AI technology is still in early stages of deployment and adoption, and the chip giant is in the most advantageous position to capture an even larger share of value as more companies turn to its products to build AI models. With AI integrating across every sector of the economy worldwide, demand for chips will only grow. Every macroeconomic correction, therefore, could be an excellent buying opportunity.

Competitors: Barrick Gold, AngloGold Ashanti, Kinross Gold, Gold Fields, Newcrest Mining, Agnico Eagle Mines.

The company publishes quarterly investor updates with financial statements, presentations, and shareholder conference calls.

The Economy and the Gold Price

Interest Rates

Gold has historically been considered one of the most reliable assets in times of crisis and uncertainty. Against the backdrop of escalating geopolitical tensions (the Russia-Ukraine war, the Israel-Hamas conflict, the dispute over Taiwan) and a likely slowdown in major economies, demand for gold as a safe haven is rising significantly.

Expected Fed rate cuts have historically been positive for gold prices as well, since lower rates reduce the yield on competing assets such as bonds and bank deposits. When yields on interest-bearing alternatives fall due to cheap money, demand rotates into gold as a more attractive store of capital. The chart showing the relationship between Fed rate cuts, marked by the red vertical line, and gold prices illustrates this clearly.

GDP

Another fundamental driver: every time US GDP has deviated significantly below the fifty-year average growth rate of 2.7%, gold prices have risen. Two clear examples from recent history are 2009 and 2020. During the 2020 pandemic, US GDP contracted 2.8% below the average, while gold prices rose 24.4%. The post-financial crisis period of 2009 produced a similar 2.6% GDP shortfall, during which gold rose 27.6%. Recessions are marked in red on the chart, showing the co-movement of GDP and gold prices.

Fed rate policy, potentially weak GDP growth, and contained inflation all point toward the start of a rate-cutting cycle this year. As returns on fixed-income investments look less attractive next year, demand for gold may increase, given that the opportunity cost of holding it will fall.

DXY

The broader US macroeconomic picture also looks less favorable against the backdrop of rising government debt. A weaker dollar is entirely plausible, and that too is a positive for gold, given their negative correlation, as shown in the chart. The logic: since gold is denominated in US dollars, a cheaper dollar raises gold’s value in other currencies, making it more attractive and lifting demand.

Central Bank Gold Purchases

Total central bank gold purchases in 2023 came to 1,136 tonnes. The highest level of net purchases on record since 1950, specifically since the dollar’s convertibility into gold ended in 1971. The 13th consecutive year of net central bank buying.

The buildup of gold reserves is driven primarily by the following:

1. Reserve diversification and risk hedging, as gold is viewed as a reliable asset amid geopolitical tensions and financial instability.

2. Inflation protection: gold preserves value over the long term, unlike paper money, shielding reserves from debasement.

3. Rebalancing away from dollar-denominated assets, reducing exposure to dollar fluctuations and US monetary policy (for China, this is part of a de-dollarization strategy and a reduction of financial dependence on a rival state).

4. Preparation for a potential transition to a new monetary system, possibly a gold standard, in the event of a crisis in the current fiat system.

Central bank reserve accumulation will most likely continue into 2024, helping them prepare for potential global financial shocks.

Gold has a unique advantage that no other asset possesses: in extreme scenarios, when financial systems or economies collapse, gold does not lose its value. Unlike paper money, equities, bonds, and other financial instruments, which depreciate rapidly during collapses, hyperinflation, and deep crises, gold continues to preserve purchasing power and function as a reliable store and medium of exchange. That is why I think holding 5-10% of an investment portfolio in gold is a sound idea.

Annual Financial Review

Income Statement

Compared to 2020, the years 2021 and 2022 saw a broad-based deterioration across most financial metrics: gross profit, operating income, net income, and EBITDA. The sharpest decline was in net income, from $2.83B in 2020 to $1.16B in 2021 and then a loss of -$429M in 2022.

This reflects higher operating expenses and a general downturn in the gold mining sector in response to the Fed’s rate hikes, as management itself acknowledged on the 2022 earnings call.

Based on management’s comments in Q4 2022, Newmont faced several headwinds that weighed on profitability. Inflation drove up prices for raw materials, energy, and other inputs required for mining operations. Steel, explosives, and fuel all got more expensive. As a result, Newmont’s operating costs for sourcing these inputs to keep its mines running increased. Inflationary pressure also forced the company to raise wages to retain staff, adding further to operating expenses.

In the end, despite stable production volumes in 2022, Newmont’s earnings declined due to higher operating costs across materials, energy, and labor. And since inflation affected the entire sector, other mining companies faced the same pressures in 2022.

Newmont conducted an impairment test on several assets and concluded that their carrying values were overstated by approximately $1.3B relative to fair market value. The CC&V mine was written down by $500M. The Cerro Negro and Porcupine goodwill was impaired by $800M. Goodwill is an intangible asset that arises when a company is acquired at a premium to the net book value of its assets: the impairment indicates that Newmont overpaid for these assets at the time of acquisition, and their actual value is lower.

The $1.3B is not a real cash loss. It is a revaluation and adjustment of carrying values to current market values. This primarily affects accounting metrics rather than actual cash flows, so it has no fundamental significance.

What does matter fundamentally is the Fed’s battle with inflation. Higher interest rates bring inflation down.

Lower inflation means Newmont’s input costs (wages, materials, fuel, etc.) grow more slowly. But lower inflation also generally depresses commodity prices, including the metals Newmont mines.

High Fed rates are associated with economic uncertainty, which pushes investors toward fixed-income assets like bonds, whose yields rise with rates. A tightening cycle creates additional risks and pressure for Newmont’s business.

Balance Sheet

From 2020 to 2022, total assets declined approximately 7% (from $41.4B to $38.5B). Liabilities rose 8% over the same period (from $17.5B to $18.9B). Equity contracted more sharply, down 18% (from $23.9B to $19.5B). Net debt grew 4.5 times (from $0.5B to $2.3B).

Newmont’s financial position deteriorated: assets shrank, debt load increased, equity fell. This reflects lower revenue on the back of declining gold prices alongside higher capital and operating costs driven by rising interest rates.

Cash Flows

Operating cash flow declined from $4.9B in 2020 to $3.2B in 2022, reflecting a deterioration in operating profitability under cost pressure. Investing outflows surged from $0.2B in 2020 to $3.21B in 2022, likely reflecting active investment in production expansion. Financing outflows (dividends, debt repayment) first rose from $1.79B in 2020 to $3.06B in 2021, then fell back to $2.13B in 2022. Against this backdrop, free cash flow declined from $3.6B in 2020 to $1.1B in 2022. In 2022, cash generation contracted while capital expenditures increased.

Quarterly Financial Review

Income Statement

Based on the Q3 2023 earnings call transcript, the key drivers of the quarterly financial changes are as follows. Revenue declined due to lower gold production volumes. Gross profit fell on the back of lower revenue and higher production costs. Operating income dropped as a direct result of the gross profit decline. Net income was hit by lower operating income compounded by one-time settlement costs related to the labor dispute at the Peñasquito mine. EBITDA contracted due to reduced operating income from lower gold output versus prior quarters.

Management’s explanation for the Q3 2023 shortfall centered on production stoppages and reduced output at the company’s largest assets: the Peñasquito, Boddington, and Tanami mines, due to a strike, adverse weather, and project delays. This directly impacted gold production and sales volumes. Compounding the issue were weak operating results at the Nevada Gold Mines and Pueblo Viejo joint ventures, in which Newmont holds 38.5% and 60% stakes respectively.

Production costs and inflationary pressure also increased, weighing on margins. Settlement costs from the Peñasquito labor dispute further reduced net income. Management characterized these problems as temporary and emphasized a focus on improving operational and financial results in Q4 and through 2024.

Balance Sheet

The asset decline is driven primarily by depreciation of fixed assets, not fully offset by new capital investment. The modest increase in liabilities reflects higher accounts payable and other current obligations. The significant equity reduction stems from the net loss recorded during the period, which reduced retained earnings. Net debt growth reflects additional borrowings and lower cash and equivalents on the balance sheet.

Summarizing the Q3 2023 commentary, management focused on the decline in net income and equity as stemming primarily from temporary operational issues: the Peñasquito strike, reduced equipment performance at other assets, and unfavorable weather. The underlying ore reserves remain unchanged; only the extraction timeline has shifted. The increase in debt reflects financing requirements for an expansive capital program aimed at growing production and improving efficiency. Overall, the company’s financial position remains stable, as evidenced by the maintained investment-grade rating of A-.

Q4 is expected to show improvement in both operating and financial results as the temporary headwinds are resolved. In the medium term, the Newcrest acquisition will substantially strengthen Newmont’s business and profitability.

Cash Flows

The decline in operating cash flow reflects lower net income during the year due to production problems at key assets and a broad deterioration in operational results. Negative investing cash flows are tied to the execution of the company’s capital program, with the quarter-on-quarter reduction reflecting cost optimization in the face of production difficulties. The increase in financing outflows is driven by higher dividend payments in line with the company’s dividend policy. The positive free cash flow in Q3 reflects strong operating inflows and reduced capital outflows.

Based on the Q3 2023 earnings call, management’s commentary on cash flow dynamics pointed to the same conclusion: the operational deterioration is temporary, the ore reserves are intact, investing outflows reflect a deliberate expansion program, and the company remains confident in the fundamental investment case.

The increase in negative financing cash flows reflects higher dividends under the stated dividend policy.

Management attributed the negative trends to temporary factors and expressed confidence in the fundamental long-term attractiveness of the business.

Shareholder Call

Key Positive Takeaways

The upcoming Newcrest merger will create the world’s largest gold mining company with 10 Tier 1 deposits, a business with significant long-term growth potential and the ability to generate stable returns for decades. Newmont has a strong global operating model and experienced leadership that has already executed successful M&A, including the Goldcorp deal. This gives investors and management confidence that the Newcrest asset integration will succeed.

The Lihir and Cadia deposits in the Newcrest portfolio have significant potential for cost reduction through the Full Potential self-improvement program, which has already demonstrated strong results at Newmont’s existing assets. Newmont has a solid balance sheet and a sensible dividend policy. The company generates substantial free cash flow even in the current volatile environment.

Newmont is well positioned in the market against the backdrop of growing gold demand from central banks and investors. This creates favorable long-term prospects for the sector. The successful resolution of the Peñasquito strike in Mexico, the largest polymetallic deposit in Newmont’s portfolio, and its return to production materially improves the company’s outlook.

Key milestones reached at major development projects including Tanami, Cerro Negro, and Porcupine, which will expand the resource base and extend mine life in these regions. Strong Q3 financial results despite the headwinds: revenue of $2.5B, adjusted EBITDA of $933M. A demonstration of business resilience. Successful commissioning of five new autonomous haul trucks at Boddington, enabling faster operations and access to higher-grade ore.

First-ever A- rating from Fitch, underscoring Newmont’s strong financial position and flexibility.

Key Negative Takeaways

Production guidance for 2023 lowered to 5.3 million gold ounces from existing assets, due to the Peñasquito suspension, weaker-than-expected performance in Nevada, and reduced output at Pueblo Viejo.

Gear ring wear on one of the Ahafo mills reduced throughput to 60% in Q3, with approximately 70-80% capacity expected in the near quarters. Delays at the Tanami expansion project, requiring additional assessment of the lower shaft section, which may result in schedule and budget revisions.

Underperformance at uncontrolled joint ventures, Nevada Gold Mines and Pueblo Viejo, weighed on overall production metrics. Potentially material changes to Newcrest’s reserves and resources after audit under Newmont’s standards.

Significant restructuring and severance costs tied to the Newcrest integration. Uncertainty around the terms of a new collective agreement at Peñasquito following the strike, creating potential long-term risks.

Production volatility at Boddington in coming quarters due to higher stripping volumes and drawdown of ore stockpiles before transitioning to higher-grade ore.

Potential upward pressure on project capital costs, particularly in Australia, from rising labor costs, which could require budget revisions.

Difficulty forecasting 2024 production and costs until the Newcrest integration is complete and new mine plans are established.

Given the risks and potential benefits discussed on the call, a sensible strategy is to hold current positions (if you own the stock) or add modestly to capture the potential upside from the Newcrest acquisition in the medium term.

Shareholders

Insiders hold less than 0.1% of shares. Management’s interests are therefore weakly aligned with shareholder value. The dominant shareholder group (63%) is institutional investors, signaling that analysts and funds believe in the company’s long-term potential.

The key holders are the world’s largest asset managers and investment funds: BlackRock, Vanguard, Van Eck, State Street. This provides stable demand from conservative long-term investors. A large float means high liquidity and broad accessibility for different categories of investors.

The shareholder structure reflects Newmont’s investment appeal from the standpoint of long-term demand and liquidity.

Conclusion

Based on a comprehensive analysis of Newmont Corporation’s financial results, market outlook, competitive advantages, and growth plans, I conclude that the shares currently represent an attractive addition to a long-term portfolio. Three key arguments:

1. Despite the temporary difficulties of recent quarters, driven primarily by operational problems at specific assets, Newmont retains strong competitive positioning and leading industry efficiency metrics. This supports confidence in a financial recovery.

2. The strategic acquisition of Newcrest Mining will significantly expand Newmont’s scale and diversify the business with high-quality assets. The anticipated synergies will have a meaningful positive impact on future profitability.

3. Fundamental factors, including growing global gold demand, dollar weakness, and declining interest rates, create a favorable macro environment for the gold mining sector and for Newmont specifically.

Given these factors, I consider a purchase of Newmont shares with a medium-term (or long-term) investment horizon to be reasonable, as a portion of investment capital in your portfolio. Over that period, the company will have the opportunity to complete the acquisition and return to a growth trajectory in earnings and business value

Business and services:

• Coupang.com online platform: a marketplace covering everything from electronics to groceries and apparel.

• Rocket Delivery: express delivery within hours across South Korea.

• Network of fulfillment centers and IT infrastructure for operational optimization.

• Financial services: payment solutions, credit cards.

• Subscription services: grocery delivery, video streaming, and more.

The largest competitors are American e-commerce giants with enormous resources and technology. All three already have some presence and operations in Asia: Amazon, Walmart, eBay.

Outside of eBay, their regional footprint is fragmented. Competition from the American giants will only intensify as they expand. For now, Coupang remains the dominant player in the South Korean domestic market. Local Korean competitors are also worth factoring in: SK Telecom, GS Retail, CJ Logistics.

The company publishes quarterly investor updates with financial statements and shareholder conference calls.

Annual Financial Review

Revenue grew from $11.97B in 2020 to $20.58B in 2022 (+72%), reflecting an expanding customer base and higher average order values as the company broadened its product range and services. Growth rates significantly outpace the market. Gross profit expanded from $1.99B to $4.71B (+137%) over the same period, indicating that the business is becoming more efficient: the company extracts more gross profit from each dollar of revenue. Scale and logistics cost optimization are contributing.

Operating income saw a sharp deterioration from 2020 to 2021 (from -$516M to -$1.2B), driven by heavy investment in business expansion: food delivery, marketing, engineering, and global expansion. Investments were scaled back in 2022. Pre-tax loss spiked from -$463M in 2020 to -$1.54B in 2021, a direct consequence of the surge in operating expenses from those investments. By 2022, the loss was reduced to -$93M following cost optimization. Net loss followed the same pattern: losses multiplied in 2021 to -$1.54B, reflecting the deliberate prioritization of investment over profitability. In 2022, net loss was brought down to -$92M. EBITDA showed a similar spike to -$996M in 2021 due to accelerating operating expenses. By 2022, Coupang refocused on efficiency and cost discipline, significantly narrowing both the operating loss and EBITDA.

In FY2021, Coupang posted strong revenue growth alongside a substantial deterioration in profitability and negative EBITDA.

In the first half of 2021, the company prioritized business scaling and revenue growth at the expense of efficiency and operating profitability. In the second half, it ran into labor shortages and a sharp demand drop tied to COVID outbreaks. Emergency capacity expansion proved costly and hit earnings hard. COVID-related expenses (staff bonuses, protective equipment, additional hiring) added roughly $130M in costs in Q4 2021 alone. A high share of investment went into startups like the food delivery service Coupang Eats, which were loss-making at the time. Logistics infrastructure expansion (warehouses, etc.) outpaced the growth of the business itself, reducing capacity utilization.

In effect, a COVID-19 outbreak coincided with active business scaling, and profitability paid the price. The company’s losses hit investors hard, falling well short of their expectations. For many, the logical move was to exit, given that a recovery to prior results could take a very long time, or might not come at all.

Balance Sheet

Assets grew from $5.07B to $9.51B, reflecting active investment activity and expansion of the business and infrastructure. Liabilities increased from $5.67B to $7.10B: the company is actively raising debt to fund growth. Liabilities as a share of total funding stand at 75%, which is high. Equity was turned from -$4.07B in 2020 to $2.41B in 2022, a shift largely driven by the IPO and roughly $4.6B raised from investors in 2021. Total debt increased modestly from $2.23B in 2020 to $2.4B in 2022, indicating continued active investment, though the pace of debt growth has slowed relative to 2020. Net debt flipped from positive to negative, moving from $837.72M in 2020 to -$1.28B in 2022. A positive trend: the company grew its liquidity and assets considerably faster than its debt load.

Cash Flows

Operating cash flow was positive in 2022 at $565.44M. A good sign: the core business is now generating more cash than it consumes. Investing cash flow came in at -$848.25M in 2022, showing that Coupang continues to invest actively in infrastructure and growth. Expected for a fast-growing company. Financing cash flow contracted from $3.58B in 2021 (IPO effect) to $247.35M in 2022, meaning the company relied less on external financing during the year. Free cash flow outflow in 2022 was -$258.82M, not a critical level given the scale of Coupang’s investments in future growth, and a marked improvement from -$1.08B in 2021.

Quarterly Financial Review

Income Statement

Revenue grew from $5.8B in Q1 to $6.18B in Q3 (+6.6%). Steady growth driven by an expanding product and services offering and a growing customer base. Pace outperforms the market. Gross profit grew from $1.42B to $1.57B (+10.6%), growing faster than revenue and pointing to improving operational efficiency. Gross margins expanded from 24.5% to 25.4%.

Operating income ran from $107M in Q1 to $147M in Q2, then pulled back to $87M in Q3. Positive trajectory versus Q1, with some softening in Q3 relative to Q2. Overall the data shows improving operating results versus the start of the year, driven by cost optimization and scaling of high-margin segments such as advertising. Q3 saw a modest slowdown due to investment in new initiatives. Relative to 2022, the trend is clearly positive. The Q2 profit increase was driven by a $100M quarter-on-quarter jump in gross profit against contained operating expense growth (only +$41M). In Q3, both effects were weaker: gross profit added $50M quarter-on-quarter while operating expenses rose $60M.

EBITDA declined from $255M in Q1 to $155M in Q3 as investment in business development increased. It remains in positive territory, providing room to fund further expansion. The overall picture is steady revenue and margin growth on the back of an expanding customer base, with Coupang continuing to invest in development, which is temporarily weighing on EBITDA.

Balance Sheet

Total assets show steady growth from $9.71B to $11.56B, a positive indicator reflecting business expansion. Liabilities are also rising ($7.15B in Q1 vs. $8.63B in Q3), which is consistent with asset growth. A slight acceleration in liability growth may indicate active use of debt financing. Equity shows positive momentum, increasing from $2.56B to $2.93B, driven by three consecutive quarters of net income. Another positive factor. Total debt is growing in absolute terms. Net debt (after deducting short-term investments and cash), however, is declining and moving into negative territory: the company carries no net debt position.

Cash Flows

Operating cash flow showed positive momentum in Q2 versus Q1 (up 59.5%), reflecting higher receipts from core operations. Q3 then saw a 9.6% decline versus Q2, pointing to temporary friction in sales and other operations. Investing cash flow remained negative throughout, with expenditures exceeding inflows. The largest outflow was in Q2, reflecting heavy investment, partly financed by debt. In Q3, the outflow contracted 63.7% versus Q2. Financing cash flow rose 214.5% in Q2 versus Q1, indicating active borrowing during the quarter, then fell 85.8% in Q3 as new borrowing slowed. Despite the pullback in operating and financing cash flows in Q3, free cash flow grew solidly: up 23.3% in Q3 versus Q2. The company has a reasonably strong liquidity buffer.

Multiples

Valuation and Key Metrics

Coupang’s valuation multiples show the stock trading at a premium to sector averages.

P/E (TTM and FWD) is roughly 4-5 times above sector medians. Investors are willing to pay up, pricing in strong future earnings growth. EV/EBITDA (TTM and FWD) likewise shows a large premium to the sector: the market is paying a significant multiple for Coupang’s growing operating earnings. Price/Book (TTM and FWD) is nearly 5 times the sector median, indicating that investors place a high value on the company’s intangible assets and growth potential.

The picture is one of strongly optimistic market expectations and a willingness to pay a substantial premium for exposure to Coupang.

Growth Rate and Key Metrics

Revenue Growth (YoY)

Revenue Growth (YoY): Coupang’s revenue is growing 13.85-13.80% year-over-year, roughly 3 times faster than sector medians. This points to strong demand and business momentum.

CapEx Growth (YoY): Capital expenditure growth fell 10.07% year-over-year, while the sector average shows 8.10% growth. Declining capex in consumer sectors typically raises flags for investors. Here it may indicate that Coupang has eased off expansion investment after an active growth phase.

Coupang is posting strong revenue growth alongside slowing investment. On one hand, a positive sign: the company is focused on monetizing existing demand. On the other, sustainable long-term growth will require continued infrastructure investment, which could weigh on profitability again down the road.

Q3 2023 Earnings Call

Positive

Key metrics continue to grow: revenue, gross profit, active users. Growth rates are accelerating versus prior quarters. Active user growth in Q3 was 14%, versus 10% in Q2 and 5% in Q1. Product assortment is expanding, which is feeding through positively to the company’s key metrics. Developing segments are gaining momentum, including food delivery via Eats and the new Taiwan market. Eats, for example, has reached a 20% share of the food delivery market. The company is generating record cash flows: $2.6B in operating cash flow in Q3. Management is confident in achieving the long-term EBITDA margin target of above 10%.

Negative

Adjusted EPS came in at $0.05, missing analyst estimates by $0.02. The company fell short of net income forecasts. Gross profit in the Product Commerce segment declined versus the prior quarter, indicating margin pressure in the core business. Losses in the Developing Offerings segment widened to $161M from $91M a year earlier, reflecting significantly higher investment in new business lines. Adjusted EBITDA declined for the total business, though management expects improvement ahead. Margin pressure from product and service assortment expansion. These near-term headwinds may continue to weigh on profitability.

Based on the earnings call transcript, Coupang’s results look promising, and I see no reason to sell the stock at this point (if you’re holding it). The company is delivering consistent growth across key metrics and strengthening its competitive position. The earnings call revealed that the Taiwan expansion is producing encouraging results and the market reception has been positive. Coupang noted that its app became the most downloaded in Taiwan in 2023. Good news for investors. Management also indicated readiness to cut investments that are underperforming expectations: “We are disciplined about capital allocation. We start with small investments, then test and iterate carefully. We invest more capital over time into opportunities with the best long-term cash flow potential. Within our international initiatives, we closed our operations in Japan, where we were not generating the returns we had hoped for. In contrast, we like what we see in Taiwan, which is showing the same signs of transformative potential that we saw in Korea when we launched Rocket Delivery.” That kind of discipline inspires confidence.

Risks

Macro risks: economic slowdown in Korea or Taiwan, reduced consumer spending; rising inflation and interest rates constraining demand and profitability.

Competition: intensifying pressure from local or international players.

Operational risks: supply chain and logistics disruptions (e.g., pandemics); challenges scaling into new markets (Taiwan).

Geopolitical risks: deterioration in North-South Korea relations, renewed conflict; military provocations and threats from North Korea; escalating tensions around Taiwan, invasion risk. Relevant given that Coupang is actively expanding into these regions.

These risks exist everywhere, in every company. None of them should be ignored: each has a direct bearing on the company’s financial performance.

Shareholders

The majority of shares (80.97%) are held by institutional investors, a signal that the company is attractive to large investment funds and other institutional players.

The largest holder is SB Investment Advisers (UK) LTD with 26.42% of all shares. This entity holds significant influence and control over the business. Detailed information on SB Investment Advisers (UK) LTD is limited. It likely represents large investors, possibly institutional or high-net-worth individuals.

Other major holders include investment and asset management firms from the US and UK, indicating broad global institutional interest.

Insider and management ownership stands at just 0.83%, meaning control and governance are effectively in the hands of outside investors.

The ownership structure reflects strong institutional conviction alongside minimal management and controlling-party ownership. The key beneficiary is the opaque SB Investment Advisers.

Conclusion

Coupang is showing signs of improving fundamentals. Its near-term strategy is centered on expanding the customer base and improving profitability while maintaining a focus on high service quality. Coupang stands out in South Korea’s competitive e-commerce market through its innovative logistics network and rapid delivery capability. The company is also benefiting from its advertising business, which is growing strongly with high operating margin potential.

Consistently growing active customer counts and sustained revenue growth, despite periodic fluctuations, point to continued expansion. The outlook in South Korea and Taiwan looks promising, supported by management’s commitment to service quality and ongoing innovation.

An additional argument for Coupang: the company is a top-2 holding for Stanley Druckenmiller, whose fund has averaged roughly 30% annual returns over many years. His current position represents 13% of his portfolio. The company also ranks 13th in the Bill and Melinda Gates Foundation portfolio at 0.4%.

Despite a difficult global economic environment, Coupang’s position is strong: a solid cash cushion, no net debt, reputable investors, and gradually improving revenue and earnings. All of this makes the company an attractive candidate for long-term investment.

Core areas of work at Intellia:

In vivo gene editing to treat hereditary diseases caused by single-gene mutations, including Huntington’s disease (brain cell death) and hemophilia (clotting deficiency). The company is running clinical trials for these indications. Development of in vivo gene editing technologies inside patient cells to create cell-based therapies, including for oncology and autoimmune diseases.

Building CRISPR delivery systems for precise modification of target cells and tissues. When scientists use CRISPR-Cas9, they need to get the technology inside the relevant cells and tissues. Think of it as transmitting instructions into a cell to make targeted changes in the genetic material. Intellia develops specialized delivery systems and methods to deploy CRISPR-Cas9 accurately at the right locations inside the body, enabling precise gene editing with the intended outcomes.

Development of CRISPR tools capable of making more precise and complex genomic edits, expanding the possibilities of gene therapy.

Lead programs in early clinical development:

NTLA-2001: for treatment of transthyretin amyloidosis (a genetic disease in which a protein accumulates in the body and causes problems in organs including the heart and peripheral nerves).

NTLA-2002: for treatment of hereditary angioedema (swelling of internal or external body tissues).

Key competitors:

The gene editing market is in early stages and marked by intense competition among the main players. As a result, many companies are forced to both collaborate and compete simultaneously.

CRISPR Therapeutics, Regeneron Pharmaceuticals, Editas Medicine, Sangamo Therapeutics, Beam Therapeutics, Precigen, Caribou Biosciences, Verve Therapeutics, Cellectis.

The company publishes a quarterly business update presentation covering all aspects of operations, research directions, and the disease areas it is targeting.

Annual Financials Analysis

Consolidated Statements of Operations and Comprehensive Loss

Revenue was $52.12M in 2022, up 57.69% from 2021 ($33.05M). Growth was driven by increased licensing payments and grants. Gross profit reached $44.55M, up 70.28% from 2021 ($26.16M). Operating loss was $458.16M, widening 71.05% from 2021 ($267.85M). Net loss fell 77.01% year-over-year to $474.19M in 2022. EBITDA came in at -$450.59M, down 72.67% from 2021 ($260.96M).

Intellia carries substantial losses despite gradual revenue growth. The explanation is straightforward: no commercial product has reached the market yet. Revenue comes entirely from partnership agreements and grants. The bulk of expenses goes to R&D and lengthy, costly clinical trials that have not yet received regulatory approval.

Intense competition in genomic editing forces Intellia to maintain high R&D investment to preserve its lead. The company has not yet reached the scale needed to reduce costs and turn profitable.

At this stage, Intellia’s losses are natural and normal for a developing biotech company, especially considering that most of the healthcare sector runs at a loss. The path to profitability runs through the commercialization of its pipeline.

Consolidated Balance Sheets

Total liabilities grew from $254.22M in 2021 to $284.53M in 2022, largely reflecting expanded business operations. Equity rose from $1.04B to $1.24B, indicating growth in the company’s value. Net debt is negative: cash and short-term investments substantially exceed total debt. Headcount increased from 485 in 2021 to 598 in 2022.

Intellia is growing actively despite current losses. The significant increase in total liabilities reflects higher investment in R&D and expanded clinical trials. The company is scaling its operations in genomic editing.

At the same time, equity is rising despite negative net income. This signals increasing market value: investors are pricing in the potential of Intellia’s CRISPR pipeline and patents.

With substantial cash on hand and low debt, the company is in a stable financial position to continue expanding. The headcount increase confirms this, reflecting a growing scientific workforce in genomic editing.

Consolidated Statements of Cash Flows

Operating cash flow declined from -$215.93M in 2021 to -$323.40M in 2022. Investing cash flow improved from -$550.78M to $160.31M. Financing cash flow shifted to an outflow, down 21.24% ($573.07M). Free cash flow declined from -$228.68M in 2021 to -$336.96M in 2022.

Cash movements in 2022 showed a significant net outflow, driven by ongoing business losses against the backdrop of active expansion and investment.

Negative operating cash flow widened as growing losses required more cash to sustain operations. Investing inflows improved because Intellia deployed less capital into acquisitions and recovered more from financial investments during the year.

The character of financing cash flow also shifted: instead of raising capital through equity issuance, the company directed cash toward liability repayment.

Free cash flow contracted substantially. Liquidity nonetheless remains sufficient to sustain investment and business development in the medium term.

Quarterly Financial Review

Consolidated Statements of Operations and Comprehensive Loss

Revenue in Q2 2023 grew 7.84% versus Q1 ($13.59M). This reflects incoming payments from partners under licensing agreements, as well as government development grants. Gross profit grew 8.22% quarter-over-quarter versus Q1 ($11.42M), indicating effective cost control. Operating loss remained negative in Q2 2023, deepening 18.2% to -$132.33M, driven by increased investment in scientific development tied to an expanding clinical research portfolio. Net loss widened 19.93% in Q2 2023 to -$123.68M due to additional hedging expenses and equity-based employee compensation. EBITDA declined 18.43% in Q2 2023 to -$130.16M, reflecting sustained high operating expenses.

Consolidated Balance Sheets

Total liabilities fell 3.83% in Q2 2023 (from $227.05M to $218.35M), driven by a reduction in accounts payable and other short-term obligations. Equity also declined 7.22% in Q2 2023, a consequence of the net loss recorded in Q1 2023. Net debt remains negative, which is a positive indicator: cash and equivalents exceed total debt by a significant margin.

Even with the equity contraction, Intellia’s current financial position can be assessed as stable, given the controlled debt load. For the company, that is what matters.

Consolidated Statements of Cash Flows

Operating cash flow in Q2 2023 improved 17.52% to -$86.53M from Q1 (-$104.91M), but remains negative, reflecting the company’s continued losses from product development spending. Investing cash flow increased 71.75% but remains negative at -$34.54M for the quarter, indicating optimized capital expenditures in the current period. Financing cash flowin Q2 2023 improved 41.75% (-$1.28M) versus the prior quarter, reflecting additional financing raised. Free cash flowimproved from -$108.74M to -$90.83M in Q2 2023. Negative free cash flow means the company is spending more than it earns. For fast-growing innovative companies like Intellia Therapeutics, reinvesting proceeds into development is standard practice. Intellia is investing in innovation, manufacturing capacity, and clinical trials for its genomic editing pipeline. These are strategic investments in future growth.

At first glance it seems contradictory that a company with negative free cash flow can carry negative net debt (more cash than debt). It is a perfectly plausible situation. Negative free cash flow means the company is spending more than it earns in the current period, but it may hold accumulated cash from prior periods that exceeds outstanding debt. The company can also borrow against future revenues or assets: this increases debt but does not immediately affect the cash balance. And Intellia receives investor financing, which increases cash without increasing debt.

Risks and Opportunities

Investing in a company like Intellia Therapeutics is a high-risk trade. There is a real possibility of losing more than 50% of an investment in the event of clinical trial failure, and we saw exactly that this year with Mersana (MRSN) and Vir Biotechnology (VIR), both of which lost significant portions of their value after adverse clinical results.

Five key risks, in order of significance:

1. Clinical development failure. If NTLA-2001 advances through trials and then reports bleeding events, insufficient safety, or insufficient efficacy, the stock will fall sharply. The reverse is equally true.

2. Regulatory action. The FDA (US) or EMA (EU) is responsible for approving any new drug. Even if a drug clears all clinical trials, approval is not guaranteed. If regulators demand additional data, delay approval, or reject applications, Intellia’s value will drop significantly. An approval, on the other hand, would drive the stock up.

3. Execution. Manufacturing problems, talent acquisition and retention challenges, budget management failures, or slower-than-expected progress will all weigh on the stock over time. Better or faster execution than expected, and the stock rises.

4. Commercial risk. Say the FDA approves a drug, and the company misses analyst revenue expectations for it. The stock falls. If an approved drug outperforms expectations, the stock rises.

5. Dilution. This happens when a company issues additional shares to raise capital, whether through a secondary offering or conversion of convertible bonds. Total share count increases, and each existing shareholder’s ownership stake shrinks.

For example: if the company raises $1B by issuing 10M new shares, a shareholder previously holding 1% (with 100M shares outstanding before the offering) will be diluted to 0.91%.

Dilution is negative for shareholders: lower ownership stake and control, earnings spread across more shares (lower earnings per share), and downward pressure on share price.

That said, dilution can be justified if the capital raised enables the company to build a product that drives growth and ultimately increases shareholder value.

Q2 2023 Earnings Call

Positive

Rapid progress in clinical trials for lead programs NTLA-2001 and NTLA-2002. Pivotal trials expected to begin for both programs in the near term.

Strong physician and patient interest in NTLA-2002 for hereditary angioedema. Phase 2 trial fully enrolled.

Encouraging preliminary efficacy and safety data for both NTLA-2001 and NTLA-2002.

Strong balance sheet with cash exceeding $1B, providing more than two years of runway.

Diverse clinical portfolio and promising CRISPR-based pipeline candidates. Significant potential patient population for NTLA-2001 and NTLA-2002 upon approval (hundreds of thousands of patients). Active engagement from leading medical centers in Intellia’s trials.

Negative

No approved products on the market. The company is running at a loss, as it remains in early-stage development.

Additional reproductive animal studies required for NTLA-2002 per FDA request. This may slow development somewhat.

NTLA-2001 for ATTR-CM is currently behind competitors already in trials. Large, lengthy, and expensive Phase 3 trials will be required for approval of key programs.

High operating expenses and rapid cash consumption will require additional financing in the future.

Competition in gene editing therapeutics will intensify. Risk of trial failure and failure to obtain regulatory approval for key programs. Uncertainty around the commercial potential and pricing of experimental drugs.

Valuation and Key Metrics

Many metrics are absent and Price/Sales and EV/Sales are very low: Intellia has no meaningful sales yet. The company is in early-stage drug development with nothing on the market. That is why both ratios are minimal. The company’s core value lies in its intellectual property and pipeline candidates, which generate no revenue at present. High R&D spending and long drug development timelines in the industry suppress the current valuation.

As Intellia’s drugs move toward commercialization and begin generating meaningful sales, Price/Sales and EV/Sales should expand to reflect that potential. At this stage, the low readings are entirely explained by the business model.

The metric that deserves more attention is Price/Book.

Current (TTM) Price/Book is 3.06, above the sector median of 2.05. The market is pricing Intellia’s shares at a higher premium to book value than sector peers. Forward Price/Book is 3.30, also above the sector median of 2.64. Investors may be pricing in continued appreciation relative to book value.

High P/B multiples can be justified for fast-growing innovative companies whose primary value sits in intangible assets (R&D), which barely register on a balance sheet.

Growth Rate and Key Metrics

Many metrics are again absent due to the company’s losses. With negative earnings figures, most multiples simply cannot be calculated.

For the metrics that are available:

Revenue growth is significantly ahead of the sector median, both in the trailing year (YoY) and in forward estimates (FWD), reflecting rapid business expansion. Working capital growth is positive, against a sector-wide decline, indicating the company is building inventory and receivables in anticipation of higher future sales. CapEx growth is running well above the sector median, showing that Intellia is actively investing in manufacturing and development to expand the business.

Taken together, the data shows Intellia growing dynamically and outpacing peers. The company is investing aggressively in its future. That is not a negative.

Shareholders

5.34% of shares are held by insiders (executives and employees). A relatively low figure: insiders control only a small fraction of the equity. 87.9% is held by institutional investors, large investment companies and funds. That is a high level of institutional ownership. 92.86% of the float is held by institutions, leaving only a small portion of freely traded shares in the hands of retail investors.

427 institutional investors hold Intellia shares, signaling broad interest from major market players.

The largest holders are ARK Invest (10.76%), The Vanguard Group (9.25%), and BlackRock (9.1%). Together they control nearly 30% of the equity.

Intellia’s shareholder base is dominated by institutional investors: a sign of strong conviction from major market players. Retail investors play a minor role. A rhetorical question: would players like ARK Investment be putting money in if they saw no future here?

Conclusion

Intellia Therapeutics is already showing promising clinical trial results for NTLA-2001 and NTLA-2002 in rare genetic diseases. Scientists and management expect to begin the pivotal trial phase in the near term, which could ultimately lead to regulatory approval and broad commercial use. If the FDA approves, new prospects open up for both the company and the gene editing market.

From a financial standpoint, the company looks reasonably stable. Cash exceeds $1B and debt is low. Intellia is running at a loss, but growing and scaling actively. That is normal for a developing biotech company.

One more point: Intellia shares are currently trading above book value (Price/Book). Investors see growth potential ahead.

And finally, the majority of Intellia shares are held by large investment funds and institutional investors. Another signal of professional confidence in the company’s prospects.

Despite the high risks inherent to the biotech sector, Intellia shares look like a compelling long-term opportunity. Close monitoring of clinical trial results and financial metrics is required.

I view Intellia Therapeutics as one of the top buy candidates in the healthcare sector in a recession scenario.

Let’s start with how the company positions itself and what it produces. This can be found in the 10-K filing submitted to the SEC.

Reading through this, the infrastructure Zoom has built around its platform is extensive. It spans hardware, applications, and cloud storage designed to streamline workflows. The company is also actively integrating AI into its platform.

The shareholder discussions reviewed below further confirm the AI integration. This points to a deliberate strategic direction and the company’s ability to adapt to shifting user and market demands.

Zoom is actively investing in infrastructure and new technology to deliver more effective and innovative solutions to its users. For investors, that is a positive signal: innovation and product development can drive growth and competitive positioning.

But what do the financials actually look like? And why did the stock drop so sharply?

Financials Analysis

CONSOLIDATED BALANCE SHEETS

I’ll be reviewing all sections through SeekingAlpha. The numbers are the same, but SeekingAlpha shows seven years of history rather than two.

In this section, the key metrics to focus on: Total Liabilities, Equity, Total Employees, Retained Earnings, Debt, and Goodwill.

Each of these lines trends upward, consistent with a company that is actively growing and expanding.

Taken in isolation, without the income and cash flow context, the balance sheet looks fairly positive and logical. Goodwill is growing, equity and liabilities both show steady growth over the past several years. Debt growth has been modest year-over-year since 2020, and net debt is negative.

All of this reflects investment in R&D, innovation, assets, facilities, and headcount.

The balance sheet alone doesn’t give you the full picture of where the real problems and advantages lie. On to the next statement.

CONSOLIDATED STATEMENTS OF OPERATIONS

What stands out in this section: Revenue, Gross Margin, Operating Income, Net Income. In SeekingAlpha, EBITDA is the additional metric worth tracking.

The data makes one thing clear. During COVID-19 (2020-2021), Zoom’s numbers went parabolic. Essentially everyone was learning, meeting, and working remotely. Zoom displaced incumbents like Skype and Microsoft Teams by being more capable and more user-friendly: simpler to use, more feature-rich, more secure, better quality.

So why did the stock collapse despite the profitability growth?

Several reasons.

• Competition. Zoom moved onto someone else’s turf. Competing with Microsoft, with a refined Microsoft Teams product and a very flexible pricing strategy, is hard.

• COVID restrictions lifting. People are no longer in isolation. Zoom calls don’t happen at the same frequency. Revenue growth slowed, margins compressed. In 2021, restrictions were just beginning to ease. By 2022, the effect was tangible.

• Overvalued stock. Macro factors also played a role: money supply expansion and inflation meant more cash in retail hands, more people investing in equities. The violent re-rating that had grossly overpriced the stock triggered position-unwinding once the first earnings reports came in below expectations.

The numbers that came out confirmed every concern investors had about profitability. Everyone expected the hyper-growth to continue. Instead, every key metric declined.

Now back to the balance sheet, in the context of current revenues and earnings.

The growth in liabilities and equity can be attributed to increased investment in R&D and proprietary technology. Still, they look high relative to the current financial results. But how do you explain the headcount growth through 2022? In a period of elevated rates, economic slowdown, and ballooning costs, Zoom kept hiring, which hit operating income disproportionately.

One thing worth noting: net debt. The numbers show a company with no net debt obligations. Cash exceeds total debt. Goodwill is also trending in the right direction.

On to the next statement for the full picture.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Easily the most important section. The key lines: Cash from Operations, Cash from Investing, Cash from Financing, and Free Cash Flow.

Cash from Operations

We see the decline in operating cash flows and the stated reasons behind it. But while most companies were cutting headcount to reduce operating costs, Zoom chose not to.

Cash from Investing

The investment portfolio consists of high-rated debt securities that are considered risk-free. These are cash equivalents. Buying them is capital preservation.

Cash from Financing

A quick note on ESPP: the Employee Stock Purchase Plan allows employees to purchase company shares at a discounted price. Employees allocate a portion of their salary toward buying stock, typically with added benefits or pricing discounts. It’s one of the ways companies align employee incentives with company performance.

In this case, the company spent significant capital buying back its own shares, which is part of a capital management strategy aimed at building long-term shareholder value. Stock option exercises generated additional inflows.

Free Cash Flow (FCF)

The SeekingAlpha table shows FCF per share, which represents the free cash flow available for the company’s own development.

FCF is the cash a company generates after accounting for operating expenses, capital expenditures, and changes in working capital. It represents the funds available for dividends, growth investment, debt repayment, or other corporate purposes.

FCF = Cash from Operations - Capital Expenditures

Yes, FCF has declined materially. But the company is still generating profit in a downturn, against intense competition from tech giants. Free Cash Flow above $1 billion is a solid financial buffer for Zoom, and it’s being deployed productively.

Form 10-Q

Opening Q1 FY2024. The two things I care most about: earnings and free cash flow.

Revenue is not falling. It’s broadly in line with prior quarters.

Gross profit is above every quarter in the past several years.

Operating and net income were in decline all through 2022, hitting negative territory. Q1 showed a small profit, which is a positive development: the company is still generating earnings in a high-rate environment.

Earnings Call Q1 FY2024

Eric Yuan, Founder and CEO of Zoom, Inc.:

For context: Zoom IQ for Sales is conversation analytics within meetings, capturing key items such as best questions asked, next-step commitments, engagement level, talk-time breakdown between your team and the customer.

Kelly Steckelberg, CFO:

Analyst Ratings at Time of Analysis

When reviewing analyst targets, weight the five-star analysts.

The top-rated analysts have targets ranging from $80 to $90. Given what the calls and recent filings show, that’s a fully justified valuation.

Summary

Zoom operates in a competitive and demanding environment, building a product that goes head-to-head with Microsoft. The Zoom Meetings vs. Microsoft Teams debate has generated extensive commentary. The choice is genuinely difficult given the pricing pressure the competitor has imposed.

Looking at the financials from the last reported year: the stock decline is well-warranted. Revenue is flat, net income is down roughly 10x year-over-year. The most recent quarter, however, shows signs of bottoming after the extended earnings compression. That is a positive signal for investors.

Reading through the latest earnings call, the company is aggressively integrating AI and deploying substantial capital into product development, while maintaining over $1 billion in free cash flow as a financial buffer. Management guidance is constructive, with meaningful revenue and earnings growth projected for the year.

Institutional investors trimmed positions over the past month. The context behind those decisions isn’t visible, but the selling started in May, which looks like gradual profit-taking.

Zoom is not out of the race. Despite the sharp drawdown, there are enough arguments to support a case for potential recovery.

One more thing: beyond the financial filings, watch the product release pipeline and competitor moves closely. That's one of the most meaningful drivers of where this stock goes from here.